pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ProstAtak
drug · gene
save

aglatimagene besadenovec

Phase 3updated 3mo ago
by $CADL Candel Therapeutics, Inc.🔗 ChEMBL
Phase 3
community read0 votes

Gene drug with a maximum clinical stage of Phase 3 (across all indications), with 8 investigational indications.

indications

indications
NSCLCProstate Cancer

all catalysts(0)

nothing on the calendar yet

Trials studying aglatimagene besadenovec

  • phase2A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovecrecruitingn=45
  • phase2CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCactive not recruitingn=90
  • phase3Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Canceractive not recruitingn=711
  • phase2Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)active not recruitingn=187
  • phase2Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinomaactive not recruitingn=54

News(1)

  • Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer
    Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.
    onclive · 3mo ago
brand
ProstAtak
trade names
Canatak, Gliatak, Oncatak, Pancatak, Prostatak, Virafir
generic
aglatimagene besadenovec
indication
Prostate Cancer
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 20m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?